FDAnews Drug Daily Bulletin

SCHERING TO BOOK 35-40 MLN EUR PROFIT FROM ALK-ABELLO SALES 'EARLY' NEXT YEAR

Dec. 14, 2005
A A

Schering AG will book the profit from the sale of its 50 pct stake in the German sales company ALK-Scherax Arzneimittel GmbH to Denmark's Chr Hansen AS 'early' next year, a spokesman said. He would not be more specific, saying it depends on regulatory approval. Earlier today, Chr Hansen said it's subsidiary ALK-Albello AS, which already owns 50 pct of the company, is buying the stake for 35-40 mln eur.

Forbes (http://www.forbes.com/home/feeds/afx/2005/12/13/afx2388222.html)